ICAD - iCAD, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.40
+0.08 (+1.27%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.32
Open6.40
Bid6.35 x 1200
Ask6.40 x 800
Day's Range6.32 - 6.47
52 Week Range2.42 - 7.45
Volume21,510
Avg. Volume152,149
Market Cap123.276M
Beta (3Y Monthly)0.78
PE Ratio (TTM)N/A
EPS (TTM)-0.70
Earnings DateAug 1, 2019 - Aug 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.50
Trade prices are not sourced from all markets
  • iCAD (NASDAQ:ICAD) Has Debt But No Earnings; Should You Worry?
    Simply Wall St.

    iCAD (NASDAQ:ICAD) Has Debt But No Earnings; Should You Worry?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • Zacks Small Cap Research

    ICAD: Q2 Results: ProFound AI Drives Detection Product Sales to ~8-year High. New Therapy Catalysts Emerge

    The $7.3M of revenue in Q2 was the highest topline number since Q3’17 and this is despite Therapy sales (in Q2) at their second lowest level since Q3’2016. Gross margin was also a highlight which, at 78.1%, looks to be the highest since Q4 2010 – this is particularly noteworthy in our opinion given recent incremental cost-of-products expenses related to enhanced (3D) server functionality and other growth-oriented investments. The relative weakness in the Therapy segment, which may soon find catalysts in a (favorable) change in CMS’ radiation oncology reimbursement policy as well as potential product-extension growth opportunities, was more than offset by very strong Detection product sales, which reached a level not seen since Q3 2011.

  • Thomson Reuters StreetEvents

    Edited Transcript of ICAD earnings conference call or presentation 1-Aug-19 12:30pm GMT

    Q2 2019 ICAD Inc Earnings Call

  • GlobeNewswire

    iCAD Reports Second Quarter 2019 Financial Results

    NASHUA, N.H., Aug. 01, 2019 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported.

  • GlobeNewswire

    iCAD to Report Second Quarter 2019 Financial Results on Thursday, August 1

    NASHUA, N.H., July 29, 2019 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that.

  • GlobeNewswire

    iCAD’s ProFound AI™ for 2D Mammography Receives CE Mark Approval

    NASHUA, N.H., July 11, 2019 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced its.

  • What Percentage Of iCAD, Inc. (NASDAQ:ICAD) Shares Do Insiders Own?
    Simply Wall St.

    What Percentage Of iCAD, Inc. (NASDAQ:ICAD) Shares Do Insiders Own?

    A look at the shareholders of iCAD, Inc. (NASDAQ:ICAD) can tell us which group is most powerful. Institutions often...

  • GlobeNewswire

    SimonMed Imaging Implements the First FDA-Cleared 3D Tomosynthesis Software Using Artificial Intelligence

    SimonMed Imaging, one of the largest outpatient medical imaging providers and largest physician radiology practices in the United States, announced today their implementation of the first FDA-cleared AI program for significantly enhancing early breast cancer detection for 3D mammography. The AI program, called ProFound AI™ for digital breast tomosynthesis (DBT), is a technology developed by iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions.

  • GlobeNewswire

    iCAD to Participate in the JMP Securities Life Sciences Conference and Piper Jaffray Heartland Summit

    NASHUA, N.H., June 18, 2019 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that.

  • GlobeNewswire

    iCAD Announces Closing of Public Offering of Common Stock

    NASHUA, N.H., June 17, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (“iCAD”) (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, announced today the closing of its previously announced underwritten registered public offering of 1,881,818 shares of its common stock at a price to the public of $5.50 per share, which includes the exercise of the underwriter’s over-allotment option to purchase 245,454 shares, for gross proceeds of approximately $10.3 million. After deducting the underwriter’s discount and other estimated offering expenses payable by iCAD, the net proceeds of the offering are approximately $9.5 million. Craig-Hallum Capital Group acted as sole managing underwriter for the offering.  Laidlaw & Company (UK) Ltd. acted as financial advisor for the offering.

  • GlobeNewswire

    iCAD Introduces ProFound AI™ for 2D Mammography in Europe

    NASHUA, N.H. and LILLE, France, June 13, 2019 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions,.

  • GlobeNewswire

    iCAD Announces Pricing of Public Offering of Common Stock

    NASHUA, N.H., June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (“iCAD”) (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, announced today the pricing of its previously announced underwritten registered public offering of 1,636,364 shares of its common stock at a price to the public of $5.50 per share, for gross proceeds of approximately $9.0 million. In addition, iCAD has granted the underwriter a 30-day option to purchase up to 245,454 additional shares of common stock to cover over-allotments, if any.

  • GlobeNewswire

    iCAD Announces Proposed Public Offering of Common Stock

    NASHUA, N.H., June 12, 2019 -- iCAD, Inc. (“iCAD”) (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today.

  • Thomson Reuters StreetEvents

    Edited Transcript of ICAD earnings conference call or presentation 7-May-19 12:30pm GMT

    Q1 2019 ICAD Inc Earnings Call

  • Zacks Small Cap Research

    ICAD: Therapy Buoys Q1 Sales, Benefits Operating Loss. Detection Acceleration Still Expected in 2H

    Much of the strength in Q1 revenue relates to Therapy product sales, which at just over $1.0M were at the highest level in the last 3.5 years and accounted for 27% of the topline – up from historical mid-to-high teen %s. This, along with other Detection-related catalysts including what we expect to be burgeoning interest in ICAD’s breast density offering, should push that segment to double-digit yoy growth before current year-end. Total revenue was $6.8M, compared to our $6.1M estimate, and included $4.2M (+3.9% yoy, -15.6% qoq) from Detection and $2.6M (+13.2% yoy, +29.1% qoq) from the Therapy segment.

  • Analysts Expect Breakeven For iCAD, Inc. (NASDAQ:ICAD)
    Simply Wall St.

    Analysts Expect Breakeven For iCAD, Inc. (NASDAQ:ICAD)

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! iCAD, Inc.'s (NASDAQ:ICAD): iCAD, Inc. provides image analysis, workflow solutions, and radiati...

  • Associated Press

    Icad: 1Q Earnings Snapshot

    On a per-share basis, the Nashua, New Hampshire-based company said it had a loss of 22 cents. Losses, adjusted for non-recurring costs, were 7 cents per share. The imaging and early cancer detection company ...

  • GlobeNewswire

    iCAD Reports First Quarter 2019 Financial Results

    U.S. adoption of ProFound AI™, the Company’s deep-learning cancer detection software solution for digital breast tomosynthesis, gaining traction Conference call today at 8:30.

  • GlobeNewswire

    iCAD Appoints R. Scott Areglado as Chief Financial Officer

    NASHUA, N.H., May 06, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today appointed R. Scott Areglado as Chief Financial Officer.  Mr. Areglado has been serving as interim Chief Financial Officer since December 2018, and previously held the role of Corporate Controller at iCAD since May 2011. Mr. Areglado has served as interim Chief Financial Officer since December 2018.  Prior to this, he was Vice President and Corporate Controller from May 2011, and previously held the role of interim Chief Financial Officer from September 2016 to November 2016.

  • GlobeNewswire

    iCAD to Report First Quarter 2019 Financial Results on Tuesday, May 7

    NASHUA, N.H., May 01, 2019 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it.

  • GlobeNewswire

    iCAD Wins Three-System Public Bid with Leading Cancer Organization in Spain, Expanding European Access to Innovative Cancer Treatments with the Xoft System

    NASHUA, N.H., April 15, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the Catalan Institute of Oncology (ICO), a leading, multi-center cancer organization in Spain, has selected iCAD as the provider of electronic brachytherapy technology for the treatment of early-stage breast cancer and gynecological cancers. ICO will introduce iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® at three hospitals located in L'Hospitalet de Llobregat, Badalona, and Girona, Spain.

  • GlobeNewswire

    iCAD to Highlight ProFound AI™ Solution for Digital Breast Tomosynthesis at 2019 Society of Breast Imaging Annual Symposium

    Company’s Latest, Deep-Learning, Cancer Detection Software Solution Recently Launched in U.S. NASHUA, N.H., April 04, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will present its latest artificial intelligence software solution for digital breast tomosynthesis (DBT), ProFound AI™, as well as its PowerLook Density Assessment software, in the iCAD exhibition booth #301 during the 2019 Society of Breast Imaging (SBI) Annual Symposium, the largest breast imaging conference in the world.  Hosted by the SBI and the American College of Radiology, the conference will take place April 4-7, 2019, in Hollywood, Florida. ProFound AI is a high-performance, deep-learning, cancer detection and workflow solution for DBT.

  • GuruFocus.com

    icad Inc (ICAD) Files 10-K for the Fiscal Year Ended on December 31, 2018

    The company has cancer detection and cancer therapy segments. Warning! GuruFocus has detected 1 Warning Sign with ICAD. For the last quarter icad Inc reported a revenue of $6.95 million, compared with the revenue of $7.90 million during the same period a year ago.

  • GlobeNewswire

    iCAD Appoints Stacey Stevens as President

    NASHUA, N.H., March 28, 2019 (GLOBE NEWSWIRE) --  iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Stacey Stevens has been named President. As President, Ms. Stevens will have expanded global P&L responsibility and focus on the Company's day-to-day operations and timely execution of key business initiatives. “As we continue to build our commercial momentum with ProFound AI, strengthen our market-leading position in clinical artificial intelligence (AI) solutions, and capitalize on increasing market demand, the Board of Directors concluded that Stacey is well-positioned to drive iCAD’s continued success based on her impressive track record of strategic, commercial and increasingly operational accomplishments,” said Michael Klein, Chairman and CEO of iCAD.